Multidimensional, spatially resolved immunologic hallmarks of response to neoadjuvant immune checkpoint blockade (ICB) therapies.
Zichao Liu(Jackson Laboratory), Pei-Ling Chen(The University of Texas MD Anderson Cancer Center), Carlos Moran Segura(Moffitt Cancer Center), Shikhar Dhingra, Joseph Johnson(Moffitt Cancer Center), Jodi Balasi(Moffitt Cancer Center), Sean Yoder(Moffitt Cancer Center), Douglas C. Marchion(Moffitt Cancer Center), Wei-Shen Chen(The University of Texas MD Anderson Cancer Center), Chaomei Zhang(Moffitt Cancer Center), Jonathan V. Nguyen(University of California, San Francisco), Justin He, Xiaofei Song(Jiangsu University), Zena Sayegh(Moffitt Cancer Center), Jeffrey H. Chuang(Jackson Laboratory), Nicholas P. Reder(University of Washington)
Cited by 0
Related Papers
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group
|Blood|2017|305
Reanalysis of Clinical Exome Sequencing Data
|New England Journal of Medicine|2019|303
Identifying Genes Whose Mutant Transcripts Cause Dominant Disease Traits by Potential Gain-of-Function Alleles
|The American Journal of Human Genetics|2018|241
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
|Science Signaling|2014|199
Quantitative trait loci for flowering time and morphological traits in multiple populations of Brassica rapa
|Journal of Experimental Botany|2007|161